NEW RAY MEDICINE INTERNATIONAL HOLDING LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.038 HKD | +5.56% |
|
+5.56% | -24.00% |
| Mar. 25 | New Ray Medicine International Holding Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 18 | New Ray Medicine International Forecasts Decline in 2023 Loss | MT |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 710.5 | 710.5 | 710.5 | 710.5 | 710.5 | 158.8 |
| Enterprise Value (EV) 1 | 620.3 | 564.4 | 624.1 | 647.2 | 573.2 | 5.69 |
| P/E ratio | -5.89 x | 21.4 x | -16.1 x | -10.2 x | -250 x | -2.04 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 3.02 x | 1.91 x | 5.99 x | 5.33 x | 2.12 x | 1.77 x |
| EV / Revenue | 2.64 x | 1.52 x | 5.26 x | 4.86 x | 1.71 x | 0.06 x |
| EV / EBITDA | 79.3 x | 129 x | -36.1 x | -15.9 x | -200 x | -0.08 x |
| EV / FCF | -5.6 x | 9.38 x | 52 x | -9.03 x | -8.21 x | 0.11 x |
| FCF Yield | -17.9% | 10.7% | 1.92% | -11.1% | -12.2% | 872% |
| Price to Book | 0.98 x | 0.98 x | 1.09 x | 1.17 x | 1.12 x | 0.3 x |
| Nbr of stocks (in thousands) | 1,671,847 | 1,671,847 | 1,671,847 | 1,671,847 | 1,671,847 | 1,671,847 |
| Reference price 2 | 0.4250 | 0.4250 | 0.4250 | 0.4250 | 0.4250 | 0.0950 |
| Announcement Date | 4/26/18 | 4/23/19 | 4/23/20 | 4/23/21 | 4/26/22 | 4/27/23 |
1HKD in Million2HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 235.2 | 372.4 | 118.6 | 133.2 | 335.4 | 89.77 |
| EBITDA 1 | 7.825 | 4.363 | -17.29 | -40.76 | -2.859 | -68.46 |
| EBIT 1 | 3.987 | 0.543 | -21.72 | -44.89 | -7.08 | -73.42 |
| Operating Margin | 1.69% | 0.15% | -18.31% | -33.7% | -2.11% | -81.78% |
| Earnings before Tax (EBT) 1 | -94.39 | 39.2 | -43.79 | -69.9 | -3.608 | -80.29 |
| Net income 1 | -105 | 33.2 | -44.11 | -69.73 | -2.824 | -77.95 |
| Net margin | -44.64% | 8.92% | -37.18% | -52.35% | -0.84% | -86.83% |
| EPS 2 | -0.0722 | 0.0199 | -0.0264 | -0.0417 | -0.001700 | -0.0466 |
| Free Cash Flow 1 | -110.7 | 60.2 | 11.99 | -71.7 | -69.84 | 49.6 |
| FCF margin | -47.07% | 16.16% | 10.11% | -53.82% | -20.82% | 55.25% |
| FCF Conversion (EBITDA) | - | 1,379.88% | - | - | - | - |
| FCF Conversion (Net income) | - | 181.32% | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/26/18 | 4/23/19 | 4/23/20 | 4/23/21 | 4/26/22 | 4/27/23 |
1HKD in Million2HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 90.2 | 146 | 86.5 | 63.4 | 137 | 153 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -111 | 60.2 | 12 | -71.7 | -69.8 | 49.6 |
| ROE (net income / shareholders' equity) | -17.5% | 4.57% | -6.39% | -11.1% | -0.46% | -13.5% |
| ROA (Net income/ Total Assets) | 0.37% | 0.04% | -1.88% | -4.22% | -0.67% | -7.64% |
| Assets 1 | -28,770 | 78,311 | 2,351 | 1,652 | 418.7 | 1,021 |
| Book Value Per Share 2 | 0.4300 | 0.4300 | 0.3900 | 0.3600 | 0.3800 | 0.3100 |
| Cash Flow per Share 2 | 0.0500 | 0.0900 | 0.0500 | 0.0400 | 0.0900 | 0.0900 |
| Capex 1 | 0.08 | 8.18 | 1.18 | 0.26 | 0.06 | 8.7 |
| Capex / Sales | 0.03% | 2.2% | 0.99% | 0.2% | 0.02% | 9.69% |
| Announcement Date | 4/26/18 | 4/23/19 | 4/23/20 | 4/23/21 | 4/26/22 | 4/27/23 |
1HKD in Million2HKD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -24.00% | 7.69M | |
| -33.59% | 14.96B | |
| -23.15% | 11.07B | |
| +9.74% | 6.13B | |
| -10.91% | 5.98B | |
| +0.88% | 4.76B | |
| +53.60% | 4.36B | |
| -10.49% | 3.73B | |
| -12.53% | 3.43B | |
| -7.34% | 3.02B |
- Stock Market
- Equities
- 6108 Stock
- Financials New Ray Medicine International Holding Limited
